Posted by Michael Wonder on 12 Nov 2024
Unicycive Therapeutics announces US FDA acceptance of the new drug application for oxylanthanum carbonate for the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis
11 November 2024 - FDA sets PDUFA action date of 28 June 2025.
Unicycive Therapeutics today announced that the US FDA has accepted the new drug application for oxylanthanum carbonate and has set a PDUFA target action date of 28 June 2025.
